NCT06548529Recruiting
HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
Al18F-HER2-BCH PET/CT to Predict Response in Bladder Cancer Patients Treated With HER2 ADC
Source: ClinicalTrials.gov · Last updated 23 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADC
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 7 Aug 2024
- Start date
- 1 Jun 2024
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Diseases
- Bladder cancer
- NCT number
- NCT06548529
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Jun 2024 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Suffering from claustrophobia or other mental disorders;
Other
- Significant hepatic or renal dysfunction;
- Is pregnant or ready to pregnant;
- Cannot keep their states for half an hour;
- Refused to join the clinical research;
- Any other situation that researchers considered it unsuitable to participate in the trial.
Who the study is looking for
- Aged # 18 years old; ECOG 0 or 1;
- Is unresectable or metastatic;
- Patients with HER2 positive or suspicious positive tumors;
- was previously treated with trastuzumab and taxane in the advanced setting or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab and taxane;
- Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
- Receives anti-HER2 ADC treatment
- Life expectancy \> 3 months
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| uEXPLORER total-body PET/CT scanner (United Imaging, China) Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.